Optimal secondary prevention medication use in acute myocardial infarction patients with nonobstructive coronary artery disease is modified by management strategy: insights from the TRIUMPH Registry.

Find People
Find Research
Overview
Tutorials
FAQs
Edit My PROFILE
Login to PROFILES

Contact Us
If you have any questions or feedback please contact us.

Optimal secondary prevention medication use in acute myocardial infarction patients with nonobstructive coronary artery disease is modified by management strategy: insights from the TRIUMPH Registry.

Pitts R, Daugherty SL, Tang F, Jones P, Ho PM, Tsai TT, Spertus J, Maddox TM. Optimal secondary prevention medication use in acute myocardial infarction patients with nonobstructive coronary artery disease is modified by management strategy: insights from the TRIUMPH Registry. Clin Cardiol. 2017 Jun; 40(6):347-355.

View in: PubMed

subject areas

Adrenergic beta-Antagonists
Angiotensin II Type 1 Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors
Aspirin
Coronary Artery Disease
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Male
Middle Aged
Myocardial Infarction
Platelet Aggregation Inhibitors
Practice Guidelines as Topic
Registries
Secondary Prevention
Treatment Outcome

authors with profiles

Stacie Luther Daugherty

Contact Us
CCTSI
About CCTSI
CCTSI Affiliated Institutions
National CTSA Consortium